216 related articles for article (PubMed ID: 20674708)
1. The double-helix derailed: the story of the BRCA patent.
Matloff ET; Brierley KL
Lancet; 2010 Jul; 376(9738):314-5. PubMed ID: 20674708
[No Abstract] [Full Text] [Related]
2. Direct to confusion: lessons learned from marketing BRCA testing.
Matloff E; Caplan A
Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
[TBL] [Abstract][Full Text] [Related]
3. USPSTF recommends BRCA testing in women based on familial history.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E6. PubMed ID: 25618620
[No Abstract] [Full Text] [Related]
4. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
[No Abstract] [Full Text] [Related]
5. JAMA patient page. BRCA genes and breast cancer.
Pluta RM; Golub RM
JAMA; 2011 Jun; 305(21):2244. PubMed ID: 21632489
[No Abstract] [Full Text] [Related]
6. Improving surveillance and quality of life of BRCA mutation carriers.
Loman N; Borg A
J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of testing for breast cancer susceptibility genes.
Holland ML; Huston A; Noyes K
Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
[TBL] [Abstract][Full Text] [Related]
8. Gene patenting--is the pendulum swinging back?
Kesselheim AS; Mello MM
N Engl J Med; 2010 May; 362(20):1855-8. PubMed ID: 20375396
[No Abstract] [Full Text] [Related]
9. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
[No Abstract] [Full Text] [Related]
10. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
11. Your money or your life.
Westphal SP
New Sci; 2002 Jul; 175(2351):28-33. PubMed ID: 12625339
[No Abstract] [Full Text] [Related]
12. Supreme Court ruling broadens BRCA testing options.
Azvolinsky A
J Natl Cancer Inst; 2013 Nov; 105(22):1671-2. PubMed ID: 24198329
[No Abstract] [Full Text] [Related]
13. Choices--and uncertainties--for women with BRCA mutations.
Couzin J
Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
[No Abstract] [Full Text] [Related]
14. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
15. Critics question BRCA2 patent decision in Europe.
Steimle S
J Natl Cancer Inst; 2005 Sep; 97(18):1326. PubMed ID: 16174851
[No Abstract] [Full Text] [Related]
16. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
17. StatBite: BRCA Mutations Increase Risk of Breast/Ovarian Cancer.
J Natl Cancer Inst; 2010 Jun; 102(11):755. PubMed ID: 20498426
[No Abstract] [Full Text] [Related]
18. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
[No Abstract] [Full Text] [Related]
19. Supreme Court will rule on whether patents for BRAC1 and BRAC2 genes are valid.
Dyer C
BMJ; 2012 Dec; 345():e8266. PubMed ID: 23223689
[No Abstract] [Full Text] [Related]
20. Pretest genetic counseling informs patients with BRCA mutation.
Printz C
Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
[No Abstract] [Full Text] [Related]
[Next] [New Search]
